As the Director of the Sleep Neuroimaging Research Program at the University of Pittsburgh School of Medicine, I spent decades researching how to improve peoples’ sleep. After seeing the side effects that were often caused by sleeping pills, I was driven to provide a drug-free sleep solution without these side effects. This mission is why I started Ebb and invented CoolDrift.
Ebb started out with an FDA-cleared prescription product called Ebb Insomnia Therapy. Our clearance was granted based largely on our multi-site, independent clinical trial results showing statistically significant improvements to patients’ sleep. Later, we launched a consumer product that leveraged this technology that was available directly to the consumer without a prescription. This is CoolDrift.
Over the years, we have continued to conduct clinical trials to demonstrate that the product would improve sleep in different populations whose sleep problems have more complex root causes, such as Veterans with PTSD and women with menopause.
One of these was a pilot study involving 24 veterans (age 42.1 ± 9.7 years) with chronic insomnia and other related conditions. The participants did one baseline week followed by 4 weeks of CoolDrift use in their homes along with personalized sleep hygiene instructions. They were asked to report on their sleep difficulties and anxiety-related symptoms during this time.
Trial Endpoints Evaluated:
Insomnia Severity Index (ISI)
Number of awakenings
Wake after sleep onset
The study indicated that, relative to baseline, veterans experienced clinically significant improvements in all evaluated insomnia metrics (p < 0.001), anxiety, and depressive symptoms with the majority shifting from moderate-severe symptoms to no/mild symptoms.
We at Ebb are dedicated to providing clinically and scientifically validated solutions for those who need it most.